CSCIF (Cosciens Biopharma) EBIT: $-6.73 Mil (TTM As of Mar. 2026)


CSCIF Cosciens Biopharma Inc CSCIF
62 GF Score
Price $1.99
GF Value $2.35
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma EBIT?

Cosciens Biopharma CSCIF -5.24% 62 EBIT is $-6.73 Mil as of Mar. 2026. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.35 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Cosciens Biopharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.73 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cosciens Biopharma's annualized ROC % for the quarter that ended in Mar. 2026 was -22.87%. Cosciens Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cosciens Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -564.68%.

Cosciens Biopharma  (OTCPK:CSCIF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cosciens Biopharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-2.92 * ( 1 - 0% )/( (12.59 + 12.949)/ 2 )
=-2.92/12.7695
=-22.87 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21.431 - 1.534 - ( 7.307 - max(0, 3.613 - 11.5+7.307))
=12.59

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18.841 - 0.887 - ( 5.005 - max(0, 1.685 - 9.393+5.005))
=12.949

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cosciens Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.548/( ( (9.806 + max(0.615, 0)) + (9.244 + max(2.889, 0)) )/ 2 )
=-0.548/( ( 10.421 + 12.133 )/ 2 )
=-0.548/11.277
=-4.86 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.081 + 1.307 + 1.625) - (1.534 + 0 + 1.864)
=0.615

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.994 + 1.099 + 1.295) - (0.887 + 0 + 0.612)
=2.889

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cosciens Biopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-6.731/1.192
=-564.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma EBIT Related Terms

Cosciens Biopharma EBIT Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma EBIT Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.71 4.67 -4.23 -15.10 -10.18

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.68 -1.78 -2.14 -0.14

CSCIF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Cosciens Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's EV-to-EBIT falls into.


CSCIF
62GF Score
Cosciens Biopharma Inc CSCIF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-6.73 Mil mean?
Cosciens Biopharma (CSCIF) has a EBIT of $-6.73 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cosciens Biopharma.
Is Cosciens Biopharma's EBIT too high?
Cosciens Biopharma's current EBIT is $-6.73 Mil. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's EBIT compare to VRTX and REGN?
Cosciens Biopharma's EBIT of $-6.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cosciens Biopharma. Cosciens Biopharma's current EBIT is $-6.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current EBIT is $-6.73 Mil. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current EBIT is $-6.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • EBIT: $-6.73 Mil
  • GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score

Get the complete analysis for CSCIF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price
$2.35
GF Value